Takeda Pharmaceutical Company Limited (TAK) Stock Price & Analysis
Takeda Pharmaceutical Company Limited (TAK) — MoonshotScore 67/100 (Strong band), calculated Oct 26, 2026. Price $20.43 (+0.94%), as of the Oct 26, 2026 trading session; market cap $65.0B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Takeda Pharmaceutical Company Limited · TAK · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Takeda Pharmaceutical Company (TAK)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a cheap price, but a strained balance sheet; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $7.74B (Q1 FY2026, quarter ended Jun 30, 2026)
- EPS beat 2 of 8
- Altman Z 1.26 · Piotroski F 5
Holding back: balance-sheet strain
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 67 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 67 | Strong |
The score was 67 in the stored Oct 24, 2026 snapshot and remains 67 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Valuation -1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $20.43 | |
| Change on the day | +0.94% | |
| 52-week range | $12.99 – $20.55 | |
| Market capitalisation | $65.0B | |
| Price / earnings (trailing) | 56.49 | |
| Shares traded on the day | 2.34M | |
| Beta (volatility vs the S&P 500) | 0.09 | |
| Dividends per share (last 12 months) | $0.71 | |
| Dividend yield (last 12 months) | 3.48% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
FDA priority review, and we expect a U.S. launch also in the second half of 2026.
Julie Kim · Statement from
If we take a step back, we anticipate U.S. launch of ORZEYFUL in the second half of 2026, rusfertide launch in the second half of 2026 and zasocitinib launch in the first half of 2027, 3 potential new standards of care launching in close succession, 2 of which carry breakthrough and Fast Track Designations.
Andrew Plump · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Takeda Pharmaceutical Company (TAK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 23, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the TAK film — every key number, told as a short cinematic story
~2 min · open the film
What is Takeda Pharmaceutical Company (TAK), and what does it report?
Short answer · as of
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. Takeda Pharmaceutical Company Limited (TAK) is listed on NYSE. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 1-1, Nihonbashi-Honcho 2-Chome, Chuo-KU, Tokyo, M0, 103-8668. It employs 47,029 people and is led by Julie So-Young Kim. In Q1 FY2026 it reported revenue of $7.74B and net income of $719M. The market values it at $65.0B.
What do the latest results show for Takeda Pharmaceutical Company (TAK)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $7.74B. Against analyst estimates the company has EPS beat 2 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $7.66B Jul 30, 2026
- Latest report · revenue estimate
- $7.13B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $7.66B | $7.13B | $0.2250 | $0.1689 |
| May 13, 2026 | $6.92B | $7.14B | −$0.0492 | $0.2100 |
| Jan 29, 2026 | $7.73B | $7.54B | $0.2131 | $0.5500 |
| Oct 30, 2025 | $7.22B | $7.79B | −$0.0249 | $0.4400 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $7.74B | $719M | $0.22 (diluted) |
| Q4 FY2025 | $7.08B | -$157M | -$0.05 (diluted) |
| Q3 FY2025 | $7.70B | $670M | $0.21 (diluted) |
| Q2 FY2025 | $7.06B | -$75M | -$0.02 (diluted) |
What are the financial strengths and risks for Takeda Pharmaceutical Company (TAK)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 1.26 · Piotroski F 5. Trailing ratios: ROE 2.4% · ROA 1.2% · current ratio 1.14 · earnings yield 1.8% · free-cash-flow yield 7.0%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.26 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Rich valuation — a P/E of 56.49 runs well above the Healthcare sector’s ~21.90x, leaving little room for a miss.
What should you watch next at Takeda Pharmaceutical Company (TAK)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026. The number it tests is the $61.91 EPS analysts carry for it. Analyst estimates on file carry FY2027 revenue $4.70T · EPS 61.91 · 9 analysts.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
FDA priority review, and we expect a U.S. launch also in the second half of 2026.
Julie Kim ·
If we take a step back, we anticipate U.S. launch of ORZEYFUL in the second half of 2026, rusfertide launch in the second half of 2026 and zasocitinib launch in the first half of 2027, 3 potential new standards of care launching in close succession, 2 of which carry breakthrough and Fast Track Designations.
Andrew Plump ·
We know our shareholders are eager to discuss more details of this path forward, and I am pleased to announce that we will host a Capital Markets Day in Tokyo on December 11, 2026.
Julie Kim ·
So for the full year, we do expect to be able to hit our guidance.
Julie Kim ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
Checked against the records this page reads, on the dates shown above.
How does Takeda Pharmaceutical Company compare with its peers?
Short answer
Takeda Pharmaceutical Company's score ranks tied for 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $90.56 Oct 26, 2026 | $52.0B | 91 5-pillar Oct 26, 2026 | |
| $99.92 Oct 26, 2026 | $6.52B | 91 5-pillar Oct 26, 2026 | |
| $251.54 Oct 26, 2026 | $57.8B | 90 5-pillar Oct 26, 2026 | |
| $80.97 Oct 26, 2026 | $33.5B | 89 5-pillar Oct 26, 2026 | |
| $175.96 Oct 26, 2026 | $49.4B | 84 5-pillar Oct 26, 2026 | |
| $13.75 Oct 26, 2026 | $11.0B | 83 5-pillar Oct 26, 2026 | |
| $10.20 Oct 26, 2026 | $45.0B | 78 5-pillar Oct 26, 2026 | |
| $196.39 Oct 26, 2026 | $54.2B | 76 5-pillar Oct 26, 2026 | |
| $14.27 Oct 26, 2026 | $2.49B | 71 5-pillar Oct 26, 2026 | |
| Takeda Pharmaceutical Company (TAK) — this page | $20.43 | $65.0B | 67 |
| $21.02 Oct 26, 2026 | $6.51B | 67 5-pillar Oct 26, 2026 | |
| $39.95 Oct 26, 2026 | $46.6B | 60 5-pillar Oct 26, 2026 | |
| $34.56 Oct 26, 2026 | $4.30B | 60 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $4.70T
- EPS estimate
- $61.91
Measured against a quoted price of $20.43 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 60
- Identified insiders
- 24
- Purchases
- 0
- Sales
- 20
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 3.4% Period end Jun 30, 2026
- Previous quarter · ownership
- 3.1% Prior to period end Jun 30, 2026
- Reporting holders
- 389 Period end Jun 30, 2026
- Previous quarter · holders
- 370 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Capital Research Global Investors | 19,297,680 |
| Fmr LLC | 9,599,302 |
| Morgan Stanley | 6,994,924 |
| Adage Capital Partners Gp, L.L.C. | 6,050,771 |
| Goldman Sachs Group INC | 5,125,032 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
Common Questions About TAK (Healthcare)
These answers are editorial: 1 of these 9 answers is drawn from the TAK research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for TAK?
TAK carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TAK a good stock to buy?
Stock Expert AI does not rate TAK buy, sell or hold. Takeda Pharmaceutical Company Limited carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TAK stock price today?
The last price recorded on this page for Takeda Pharmaceutical Company Limited (TAK) is $20.43, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for TAK?
Takeda Pharmaceutical Company Limited faces several risks, including exposure to patent expirations that could significantly impact revenue from key products.
What are the key factors to evaluate for TAK?
Takeda Pharmaceutical Company Limited (TAK) holds a MoonshotScore in the moderate range. P/E: 56.49x. With a strong portfolio of products like Gammagard Liquid and Hyqvia, Takeda is well-equipped to leverage the increasing demand for these life-saving treatments, particularly in immunology and hematology. Not financial advice.
How frequently does TAK data refresh on this page?
TAK's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TAK's recent stock price performance?
Takeda Pharmaceutical Company Limited (TAK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global presence with a strong market share. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TAK overvalued or undervalued right now?
Takeda Pharmaceutical Company Limited (TAK) trades at 56.49x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TAK before investing?
Before investing in Takeda Pharmaceutical Company Limited (TAK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (57 figures)
The 57 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Julie Kim (Jul 30, 2026): FDA priority review, and we expect a U.S. launch also in the second half of 2026. Andrew Plump (Jul 30, 2026): If we take a step back, we anticipate U.S. launch of ORZEYFUL in the second half of 2026, rusfertide launch in the second half of 2026 and zasocitinib launch in the first half of 2027, 3 potential new standards of care launching in close succession, 2 of which carry breakthrough and Fast Track Designations. Julie Kim (Jul 30, 2026): We know our shareholders are eager to discuss more details of this path forward, and I am pleased to announce that we will host a Capital Markets Day in Tokyo on December 11, 2026. Julie Kim (Jul 30, 2026): So for the full year, we do expect to be able to hit our guidance. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-KU, Tokyo, M0, 103-8668 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS, 103-8668, JP". |
FMP — 41 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $20.43 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T21:14:30.798Z. | |
px.change | Change on the day | +0.94% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $65.0B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:03.000Z. Captured from FMP at 2026-10-26T21:14:29.795Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 29, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.19 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q1 FY2026 | $7.74B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 56.49 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.34M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.09 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers Specialty & Generic | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 47,029 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Julie So-Young Kim | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q1 FY2026 | $719M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $7.66B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $7.13B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $0.2250 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $0.1689 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.revenue_actual | Revenue · reported — report date 2026-05-13 | $6.92B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.revenue_estimated | Revenue · estimate — report date 2026-05-13 | $7.14B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_actual | EPS · reported — report date 2026-05-13 | −$0.0492 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_estimated | EPS · estimate — report date 2026-05-13 | $0.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_actual | Revenue · reported — report date 2026-01-29 | $7.73B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_estimated | Revenue · estimate — report date 2026-01-29 | $7.54B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_actual | EPS · reported — report date 2026-01-29 | $0.2131 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_estimated | EPS · estimate — report date 2026-01-29 | $0.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_actual | Revenue · reported — report date 2025-10-30 | $7.22B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_estimated | Revenue · estimate — report date 2025-10-30 | $7.79B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_actual | EPS · reported — report date 2025-10-30 | −$0.0249 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_estimated | EPS · estimate — report date 2025-10-30 | $0.4400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 20 sales, 40 other transactions · 24 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 14, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 3.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 3.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 389 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 370 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Capital Research Global Investors — shares in provider snapshot | 19,297,680 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Fmr LLC — shares in provider snapshot | 9,599,302 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Morgan Stanley — shares in provider snapshot | 6,994,924 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Adage Capital Partners Gp, L.L.C. — shares in provider snapshot | 6,050,771 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Goldman Sachs Group INC — shares in provider snapshot | 5,125,032 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 7 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-24 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 1.26 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
px.range52 | 52-week range | $12.99 – $20.55 | UNRECORDED | Stored company-profile observation — Captured 2026-10-26 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 2.4% · ROA 1.2% · current ratio 1.14 · earnings yield 1.8% · free-cash-flow yield 7.0% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.est_eps | EPS estimate, FY2027 | $61.91 | UNRECORDED | Stored analyst estimates — Captured 2026-10-26 | |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $4.70T · EPS 61.91 · 9 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-26 | |
earn.est_revenue | Revenue estimate, FY2027 | $4.70T | UNRECORDED | Stored analyst estimates — Captured 2026-10-26 |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.71 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-26, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.48% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($7.66B) with the recorded estimate ($7.13B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.2250) with the recorded estimate ($0.1689) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 67 of 100 · Strong · pillars 79 / 28 / 73 / 69 / 87 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 67 (stored snapshot Oct 24, 2026) → 67 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-05-13.revenue_actual,earn.history.depth.2026-05-13.revenue_estimated,earn.history.depth.2026-05-13.eps_actual,earn.history.depth.2026-05-13.eps_estimated,earn.history.depth.2026-01-29.revenue_actual,earn.history.depth.2026-01-29.revenue_estimated,earn.history.depth.2026-01-29.eps_actual,earn.history.depth.2026-01-29.eps_estimated,earn.history.depth.2025-10-30.revenue_actual,earn.history.depth.2025-10-30.revenue_estimated,earn.history.depth.2025-10-30.eps_actual,earn.history.depth.2025-10-30.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.